Citation Impact
Citing Papers
Preferential Generation of Follicular B Helper T Cells from Foxp3 + T Cells in Gut Peyer's Patches
2009 StandoutScienceNobel
Removing T-cell epitopes with computational protein design
2014 StandoutNobel
Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program
2007 StandoutNobel
Modulation of immune cell reactivity with cis -binding Siglec agonists
2021 StandoutNobel
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
2013 StandoutNobel
Innate and Adaptive Immunity Cooperate Flexibly to Maintain Host-Microbiota Mutualism
2009 StandoutScienceNobel
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
2008
Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study
2007
Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells
2005 StandoutNobel
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
2004 StandoutNobel
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
De novo design of immunoglobulin-like domains
2022 StandoutNobel
Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity
2006
Multiple myeloma
2014
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
2013 Standout
Complement and cellular cytotoxicity in antibody therapy of cancer
2008
Improving the efficacy of antibody-based cancer therapies
2001
Mesoporous silica nanoparticles in biomedical applications
2012 StandoutNobel
A molecular timescale for vertebrate evolution
1998 StandoutNature
Inferring the historical patterns of biological evolution
1999 StandoutNature
Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis
2007
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
2003 Standout
B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximab
2004
Dendritic cells: versatile controllers of the immune system
2007 StandoutNobel
Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis
2004 Standout
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
2002 Standout
The G Protein-coupled Receptor CL1 Interacts Directly with Proteins of the Shank Family
2000 StandoutNobel
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
2008 Standout
Follicular B helper T cells in antibody responses and autoimmunity
2005
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
2005
Salvage Therapy for Refractory or Relapsed Acute Lymphocytic Leukemia
2001
Signaling antibodies in cancer therapy
1999
Immune Thrombocytopenic Purpura
2002 Standout
Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma
2009
Systemic Lupus Erythematosus
2011 Standout
Follicular lymphoma international prognostic index
2006
CD22 as a target of passive immunotherapy
2003
Monoclonal antibodies as therapeutic agents for cancer
2004
Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies
2001
Clinical trials of antibody therapy
2000
Cancer immunotherapy comes of age
2011 StandoutNature
Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone
2001
Immunotherapy: past, present and future
2003
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 Standout
Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment
2016
Therapeutic vaccines for cancer: an overview of clinical trials
2014
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
2010 Standout
Cross-Priming of Cytotoxic T Cells Promoted by Apoptosis-Inducing Tumor Cell Reactive Antibodies?
2002
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
2014 Standout
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
2004
Rituximab: Mechanism of Action
2010
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Monoclonal antibodies for cancer immunotherapy
2009
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Chimeric antigen receptor T-cell therapies for lymphoma
2017
Therapeutic monoclonal antibodies
2000
Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
2012
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
2012
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)
1999
Clinical Outcome of Lymphoma Patients After Idiotype Vaccination Is Correlated With Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype
2004
Do self‐perpetuating B lymphocytes drive human autoimmune disease?
1999
Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+B-Cell Non-Hodgkin's Lymphoma
1999
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells
2011
Bendamustine: Rebirth of an Old Drug
2009
Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B‐Cell Levels Do Not Correlate With Clinical Response
2007
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)
2010
Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin’s Lymphoma Patients
2003
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
2002
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
2001
Rituximab Therapy in Hematologic Malignancy Patients With Circulating Blood Tumor Cells: Association With Increased Infusion-Related Side Effects and Rapid Blood Tumor Clearance
1999
Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma
2005
The Evolution of Dinosaurs
1999 StandoutScience
Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience
2000
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
2006 Standout
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
2010
Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma
2009
Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma
2000
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
2005
A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma
2008
Cytokine Storm
2020 Standout
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
2002
Drug Discovery: A Historical Perspective
2000 StandoutScience
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
2008
Monoclonal Antibody Therapy for Cancer
2003
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
Identification of a Novel Cortactin SH3 Domain-Binding Protein and Its Localization to Growth Cones of Cultured Neurons
1998
Chimeric Antigen Receptor Therapy
2018 Standout
The Peritoneal Cavity Provides a Protective Niche for B1 and Conventional B Lymphocytes during Anti-CD20 Immunotherapy in Mice
2005
The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy
2004
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
Emerging Targets in Photopharmacology
2016 StandoutNobel
The phylogenetic relationships of sauropod dinosaurs
1998
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura
2001
Regulatory roles of IL-10–producing human follicular T cells
2019 StandoutNobel
T Cell Activation in Rheumatoid Synovium Is B Cell Dependent
2001
Multiple Myeloma
2011 Standout
World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997
1999 Standout
Early Evolution and Higher-Level Phylogeny of Sauropod Dinosaurs
1998
Mass Survival of Birds Across the Cretaceous- Tertiary Boundary: Molecular Evidence
1997 Science
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial
2002
Elicitation of structure-specific antibodies by epitope scaffolds
2010 StandoutNobel
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes
2014 StandoutNobel
Works of Michael E. Williams being referenced
Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma
2008
Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402
2014
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
1998 Standout
Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network
2013
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
2009
Chromosome 11q13 Amplification in Head and Neck Squamous Cell Carcinoma: Association With Poor Prognosis
1995
Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab
1999
A New Species of Sauropod Dinosaur, Haplocanthosaurus delfsi sp. nov., from the Upper Jurassic Morrison Fm. of Colorado
1988
Catastrophic versus noncatastrophic extinction of the dinosaurs: testing, falsifiability, and the burden of proof
1994
Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study
2008
Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
2013